Corbus Pharmaceuticals Holdings Inc
Change company Symbol lookup
Select an option...
CRBP Corbus Pharmaceuticals Holdings Inc
NBR Nabors Industries Ltd
NVDA NVIDIA Corp
FB Facebook Inc
SCNTQ Scient Inc
HAIN Hain Celestial Group Inc
MAC Macerich Co
KCLI Kansas City Life Insurance Co
WWR Westwater Resources Inc
REI Ring Energy Inc
Go

Health Care : Biotechnology | Small Cap GrowthCompany profile

Corbus Pharmaceuticals Holdings, Inc. is a Phase-III, clinical-stage pharmaceutical company focused on the development and commercialization of novel therapeutics to treat rare, chronic, and serious inflammatory and fibrotic diseases. The Company operates through developing and commercializing therapeutics to treat rare life-threatening inflammatory fibrotic diseases segment. The Company's lead product candidate, lenabasum, is a novel, synthetic oral endocannabinoid-mimetic drug designed to resolve chronic inflammation and halt fibrotic processes. Lenabasum stimulates the production of Specialized Pro-Resolving Lipid Mediators (SPMs) that act to resolve inflammation, and halt fibrosis by activating endogenous pathways. The Company is developing lenabasum to treat four diseases: systemic sclerosis, cystic fibrosis, diffuse cutaneous, skin-predominant dermatomyositis and systemic lupus erythematosus (SLE).

Postmarket

Last Trade
Delayed
$5.05
-0.08 (-1.56%)
Bid
--
Ask
--
B/A Size
--

Market Hours

Closing Price
$5.13
Day's Change
0.18 (3.64%)
Bid close
--
Ask close
--
B/A Size
--
Day's High
5.15
Day's Low
4.91
Volume
(Average)
Volume:
504,062

10-day average volume:
541,908
504,062

Display:

Providers:

UpdateCancel
4 providers
November 26, 2019
August 20, 2019

Earnings Calendar and Events Data provided by |Terms of Use| © 2019 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

"Hot" indicates urgent and noteworthy news stories as determined by providers Dow Jones or Benzinga. TD Ameritrade does not select or recommend "hot" stories.

Information and news provided by ,, , Computrade Systems, Inc., , and

Copyright © 2019. All rights reserved.